Latest News on EOLS

Financial News Based On Company


Advertisement
Advertisement

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 13, 2026

https://www.biospace.com/press-releases/evolus-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-november-13-2026
Evolus, Inc. (NASDAQ: EOLS) announced that it granted 194,335 restricted stock units (RSUs) to 25 newly hired non-executive employees between August and November 2026. These RSUs, vesting 25% annually, were issued as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). This action aligns with the company's 2023 Inducement Incentive Plan to attract new talent.

Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows

https://www.tradingview.com/news/marketbeat:f0049e81d094b:0-evolus-eyes-2027-sculpt-launch-as-filler-portfolio-expands-and-revenue-grows/
Evolus (EOLS) anticipates launching Evolysse Sculpt in 2027, expanding its injectable aesthetics portfolio beyond Jeuveau wrinkle treatment and existing hyaluronic acid fillers. The company reported a 14% year-over-year revenue growth through the third quarter and reaffirmed its full-year revenue guidance of $330 million to $337 million, driven by a healthy aesthetics market and strategic product expansion. Evolus aims to increase its market share in the filler segment and leverage its existing commercial platform for future product introductions.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-evolus-inc---eols-302937511.html
Pomerantz LLP is investigating potential securities fraud claims against Evolus, Inc. (NASDAQ: EOLS) after a warning letter from the U.S. Food and Drug Administration (FDA) was disclosed. The FDA flagged an Instagram promotion for Evolus's Jeuveau wrinkle treatment as false or misleading, leading to a 7.15% drop in Evolus's stock price. Investors affected by the stock drop on October 2, 2026, are encouraged to contact Pomerantz LLP for information about joining a class action lawsuit.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Evolus, Inc. (EOLS) And Encourages Shareholders to Connect

https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-evolus-inc-eols-and-0
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Evolus, Inc. (NASDAQ:EOLS) after the company received a warning letter from the FDA regarding allegedly false or misleading Instagram promotions of its wrinkle treatment, Jeuveau. This news led to an approximate 7.15% decline in Evolus's stock price on October 2, 2026. The firm encourages affected shareholders to connect and participate in the investigation, operating on a contingency fee basis.

Law firm investigates Evolus over FDA warning on misleading Jeuveau promotion

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-selidiki-evolus-inc-peringatan-fda
Pomerantz LLP is investigating Evolus, Inc. following a 7% stock drop after the FDA issued a warning on October 2, 2026, regarding misleading Instagram promotions for its Jeuveau wrinkle treatment. The FDA cited the promotion for downplaying safety risks and making exaggerated claims about the product's effectiveness. The investigation will assess if Evolus or its executives committed securities fraud, potentially leading to a class-action lawsuit.
Advertisement

Evolus, Inc. (EOLS) Seasonal returns chart

https://uk.finance.yahoo.com/quote/EOLS/seasonality/
This article from Yahoo Finance presents a seasonality chart for Evolus, Inc. (EOLS), showing the average monthly price return for the period between 2018 and 2026. It highlights the stock's performance trends over different timeframes. The content also includes basic stock information such as its current price and after-hours trading.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-evolus-inc---eols-302931447.html
Pomerantz LLP is investigating potential securities fraud claims against Evolus, Inc. (NASDAQ: EOLS) after a warning letter from the U.S. Food and Drug Administration (FDA) regarding a misleading Instagram promotion for the company's wrinkle treatment, Jeuveau. The FDA flagged that the promotion improperly compared Jeuveau to everyday beauty products, minimized critical safety information, and made unsubstantiated claims about its efficacy. Following this news on October 2, 2026, Evolus's stock price fell by 7.15%.

Evolus faces investigation after FDA flags misleading Instagram ad, stock drops 7%.

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-selidiki-peringatan-fda-evolus
Evolus, Inc. is under investigation by Pomerantz LLP following an FDA warning regarding a misleading Instagram advertisement for its wrinkle treatment, Jeuveau. The FDA criticized the ad for downplaying safety risks and making exaggerated claims, leading to a 7.15% drop in Evolus's stock. The investigation will examine whether the company and its executives engaged in securities fraud.

Evolus Reaffirms 2026 Revenue Outlook, Cuts Expense Guidance

https://www.tokenpost.com/news/business/49837
Evolus has reaffirmed its 2026 revenue outlook of $330 million to $337 million while lowering its non-GAAP operating expense guidance to $210 million to $213 million. The company also announced a 2028 revenue target of $450 million to $500 million and maintained its adjusted gross margin outlook. CEO David Moatazedi highlighted four consecutive quarters of positive adjusted EBITDA and plans for three new product introductions.

Evolus Inc (EOLS) (Q3 2026) Earnings Call Highlights: Fourth Consecutive Positive Adjusted ...

https://au.finance.yahoo.com/news/evolus-inc-eols-q3-2026-130935917.html
Evolus Inc. (EOLS) reported its fourth consecutive quarter of positive adjusted EBITDA in Q3 2026, reaching $1.2 million, a $4.2 million improvement year over year. The company saw strong growth in global toxin revenue (11%) and HA business (40% in Q3), expanding its customer base and membership. Despite an FDA untitled letter for an Instagram post and competitive market, Evolus reaffirmed its full-year revenue guidance and outlined an expanding pipeline of injectable products for future growth.
Advertisement

Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook

https://www.biospace.com/press-releases/evolus-reports-third-quarter-2026-financial-results-with-13-year-over-year-revenue-growth-delivers-fourth-consecutive-quarter-of-positive-adjusted-ebitda-and-reaffirms-full-year-2026-financial-outlook
Evolus, Inc. announced strong financial results for the third quarter of 2026, reporting a 13% year-over-year revenue increase to $78.0 million and its fourth consecutive quarter of positive Adjusted EBITDA at $1.2 million. The company reaffirmed its full-year 2026 net revenue guidance of $330 million to $337 million and its 2028 long-term financial outlook, projecting total net revenue between $450 million and $500 million. Evolus also highlighted strategic advancements, including new partnerships and an expanding product pipeline in aesthetic injectables.

What Evolus (EOLS) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:637975902094b:0-what-evolus-eols-said-on-its-q3-earnings-call/
Evolus (EOLS) reported strong third-quarter results with revenue up 13% to $78 million, driven by growth in its injectable products and its fourth consecutive quarter of positive adjusted EBITDA. The company reaffirmed its 2026 revenue forecast and longer-term financial targets, while also lowering its non-GAAP operating expense outlook. Evolus is expanding its portfolio with anticipated FDA approvals for Evolysse Sculpt and Evolysse Lips, alongside ongoing development of other aesthetic treatments.

Evolus Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62897536/evolus-q3-2026-earnings-call-transcript
Evolus reported its fourth consecutive quarter of positive adjusted EBITDA in Q3 2026, with revenue growth of 13% year-on-year to $78 million. The company is expanding its portfolio beyond Jeuveau with new products like Evolysse and Profhilo, and reaffirmed its full-year revenue guidance of $330-337 million. This growth is supported by an expanding customer base, with over 500 new accounts added during the quarter, bringing the total to over 19,000.

Evolus 3Q 2026: Revenue $77.95M, Net income ($12.52M), EPS ($0.19) — 10-Q Summary

https://www.tradingview.com/news/tradingview:fe2aa863a70c6:0-evolus-3q-2026-revenue-77-95m-net-income-12-52m-eps-0-19-10-q-summary/
Evolus reported its third-quarter 2026 financial results, with revenue increasing 13% year-over-year to $77.95 million. The company's net loss narrowed to $12.52 million, and diluted loss per share improved to $0.19. Growth was driven by strong sales of Jeuveau and Evolysse, with anticipated U.S. approvals for Sculpt and Lips in 2026 and 2027, respectively, and expansion of Evolysse rights internationally.

Evolus, Inc. (EOLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

https://natlawreview.com/press-releases/evolus-inc-eols-investigation-bronstein-gewirtz-grossman-llc-encourages-1
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Evolus, Inc. (NASDAQ:EOLS) following a warning letter from the U.S. Food and Drug Administration (FDA). The FDA's letter concerned allegedly false or misleading Instagram promotions for Evolus's wrinkle treatment, Jeuveau, which reportedly downplayed safety information and made claims of "complete results." This news led to a 7.15% drop in Evolus's stock price on October 2, 2026, prompting the firm to encourage investors to seek more information about the investigation.
Advertisement

Law firm probes Evolus over FDA warning on misleading Jeuveau ads, shares drop 7%.

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-lawan-selidiki-evolus-inc
Pomerantz LLP is investigating Evolus, Inc. following an FDA warning regarding misleading Instagram promotions for its wrinkle treatment, Jeuveau. The FDA criticized the ads for downplaying safety risks and making exaggerated claims, leading to a 7.15% drop in Evolus's stock price. The investigation may result in a class-action lawsuit if securities fraud is confirmed.

Avoiding Lag: Real-Time Signals in (EOLS) Movement

https://news.stocktradersdaily.com/news_release/14/Avoiding_Lag:_Real-Time_Signals_in_EOLS_Movement_110126011801_1793510281.html
This article provides an in-depth analysis of Evolus Inc. (NASDAQ: EOLS) based on AI-generated real-time signals. It identifies a positive near-term sentiment that may counter a mid-term weak bias, all within a long-term strength context, while noting an elevated downside risk due to a lack of additional long-term support signals. The analysis includes specific position, momentum breakout, and risk hedging trading strategies with defined entry zones, targets, and stop losses across different time horizons.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-evolus-inc---eols-302923696.html
Pomerantz LLP is investigating potential securities fraud claims against Evolus, Inc. (NASDAQ: EOLS) after a warning letter from the U.S. Food and Drug Administration (FDA) was disclosed. The FDA flagged an Instagram promotion for Evolus's wrinkle treatment, Jeuveau, as false or misleading, leading to a 7.15% drop in Evolus's stock price. Investors affected by the stock drop are encouraged to contact Pomerantz LLP.

Evolus to Participate in Upcoming November 2026 Investor Conferences in New York and London

https://www.biospace.com/press-releases/evolus-to-participate-in-upcoming-november-2026-investor-conferences-in-new-york-and-london
Evolus, Inc. announced its management team will participate in two investor conferences in November 2026. The Stifel Healthcare Conference in New York City on November 11 will include a fireside chat and investor meetings, while the Jefferies Global Healthcare Conference in London on November 16-17 will feature investor meetings. A webcast of the Stifel fireside chat will be available on the Evolus Investor Relations website.

Evolus to Participate in Upcoming Investor Conferences in New York and London

https://www.financialcontent.com/article/bizwire-2026-10-28-evolus-to-participate-in-upcoming-investor-conferences-in-new-york-and-london
Evolus, Inc. announced that its management team will participate in two upcoming investor conferences: the Stifel Healthcare Conference in New York City on November 11, 2026, and the Jefferies Global Healthcare Conference in London on November 16-17, 2026. A live webcast of the Stifel fireside chat will be available on the Evolus investor relations website. The company will host investor meetings at both events.
Advertisement

Law firm probes Evolus over FDA warning on misleading Jeuveau promotion, stock falls 7%.

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-selidiki-evolus-peringatan-fda-promosi-instagram
Pomerantz LLP is investigating Evolus, Inc. following an FDA warning regarding misleading Instagram promotions for its wrinkle treatment, Jeuveau. The FDA criticized the promotion for downplaying safety risks and making unsubstantiated effectiveness claims, which led to a 7.15% drop in Evolus's stock on October 2, 2026. This investigation could result in a class action lawsuit for securities fraud or unlawful business practices against Evolus and its executives.

Evolus, Inc. Common Stock Estimates – NASDAQ:EOLS

https://www.tradingview.com/symbols/NASDAQ-EOLS/financials-estimates/
This page provides financial actuals and estimates for Evolus, Inc. (EOLS) common stock listed on the Nasdaq Stock Market. Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform offers detailed information on income statements, balance sheets, cash flow, dividends, and earnings.

Evolus, Inc. (EOLS) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/EOLS/
This Yahoo Finance article provides a detailed overview of Evolus, Inc. (EOLS) stock, including its current price, performance metrics, and key financial data. It covers the company's profile as a performance beauty company offering Jeuveau and Evolysse, along with analyst insights and recent news. The article also includes comparative performance against the S&P 500 and various valuation measures.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-evolus-inc---eols-302916515.html
Pomerantz LLP is investigating potential securities fraud claims against Evolus, Inc. (NASDAQ: EOLS) after the FDA issued a warning letter regarding an Instagram promotion for its wrinkle treatment, Jeuveau. The FDA flagged the promotion as false or misleading, leading to a 7.15% drop in Evolus's stock price on October 2, 2026. The law firm is advising affected investors to contact them for information about joining a class action.

Evolus to Report Third Quarter Financial Results on November 4, 2026

https://www.biospace.com/press-releases/evolus-to-report-third-quarter-financial-results-on-november-4-2026
Evolus, Inc. announced it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the U.S. financial markets close. The company's management will host a conference call and live webcast at 4:30 p.m. ET to discuss these results, followed by a question-and-answer session. Details for participating in the call and accessing the webcast or replay are provided.
Advertisement

Press Release: Evolus to Report Third Quarter Financial Results on November 4, 2026

https://www.moomoo.com/news/post/1001870328/press-release-evolus-to-report-third-quarter-financial-results-on
Evolus, Inc. announced it will release its third-quarter financial results for the period ended September 30, 2026, before the market opens on Wednesday, November 4, 2026. The company will also host a conference call and webcast on the same day at 8:30 AM ET to discuss the results and provide a business update.

Evolus to Report Third Quarter Financial Results on November 4, 2026

https://natlawreview.com/press-releases/evolus-report-third-quarter-financial-results-november-4-2026
Evolus, Inc. (NASDAQ: EOLS) announced it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the U.S. financial markets close. Management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET on the same day. The company, a performance beauty company, focuses on building an aesthetic portfolio of consumer brands.

Evolus to Report Third Quarter Financial Results on November 4, 2026

https://www.financialcontent.com/article/bizwire-2026-10-21-evolus-to-report-third-quarter-financial-results-on-november-4-2026
Evolus, Inc. announced it will report its third-quarter 2026 financial results on Wednesday, November 4, 2026, after the U.S. financial markets close. The company's management will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results, followed by a question-and-answer session. Details for participating in the call and accessing replays are provided.

Evolus, Inc. (EOLS) Investigation: Bronstein, Gewirtz & Grossman

https://natlawreview.com/press-releases/evolus-inc-eols-investigation-bronstein-gewirtz-grossman-llc-encourages-0
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Evolus, Inc. (EOLS) following a warning letter from the FDA regarding allegedly false or misleading Instagram promotions for its wrinkle treatment, Jeuveau. The FDA claims the company's promotional materials downplayed safety information while making unsubstantiated claims of "complete results." This news led to a 7.15% drop in Evolus's stock price on October 2, 2026, and the firm is encouraging affected shareholders to contact them.

Evolus, Inc. (EOLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

https://natlawreview.com/press-releases/evolus-inc-eols-investigation-bronstein-gewirtz-grossman-llc-encourages
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Evolus, Inc. (NASDAQ: EOLS) after the company received a warning letter from the FDA. The FDA letter concerned allegedly false or misleading Instagram promotions for Evolus's wrinkle treatment, Jeuveau, which minimized safety information and made claims of "complete results." Following this news, Evolus's stock price declined by approximately 7.15% on October 2, 2026.
Advertisement

Purchase/sale of business (net) of Evolus, Inc. – SWB:EVL

https://www.tradingview.com/symbols/SWB-EVL/financials-cash-flow/purchase-sale-business/
This article provides financial data for Evolus, Inc. (EVL) on the Stuttgart Stock Exchange, specifically focusing on the company's purchase/sale of business (net). The listing indicates that the market is currently closed with no trades recorded.

Evolus Enters Hair Restoration Market With Potential First-in-class Injectable

https://thedermdigest.com/evolus-enters-hair-restoration-market-with-potential-first-in-class-injectable/
Evolus, Inc. has announced an option agreement to enter the hair restoration market with a novel, procedure-based, sustained-release injectable treatment. The company will make an initial payment of $1.5 million and contribute expertise to develop the first-in-human clinical proof-of-concept study. If the option is exercised, Evolus will acquire and control the asset through development and potential commercialization, with formulation development expected through 2027.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-evolus-inc---eols-302909601.html
Pomerantz LLP is investigating potential securities fraud claims against Evolus, Inc. (NASDAQ: EOLS) after the FDA issued a warning letter regarding a misleading Instagram promotion for the company's wrinkle treatment, Jeuveau. The FDA flagged issues with the post's claims about product effectiveness and minimization of safety information, leading to a 7.15% drop in Evolus's stock price on October 2, 2026. Investors are advised to contact Pomerantz LLP for more information.

Evolus signs option deal for injectable hair restoration treatment

https://www.streetinsider.com/Corporate+News/Evolus+signs+option+deal+for+injectable+hair+restoration+treatment/27184344.html
Evolus, Inc. has entered into an option agreement with a private company to develop a sustained-release injectable treatment for hair restoration. Evolus will make an initial option payment of $1.5 million and support a clinical proof-of-concept study, with the option to acquire 100% of the assets related to the program after evaluating human clinical data. The program is expected to remain in formulation development through 2027 and will not impact Evolus's current revenue or profitability outlook.

Evolus Signs Option Agreement With Company Developing Injectable Treatment for Hair Restoration

https://finance.yahoo.com/healthcare/articles/evolus-signs-option-agreement-company-141529083.html
Evolus (EOLS) has entered into an option agreement with an undisclosed company that is developing an innovative injectable treatment for hair restoration. The article mentions that further details are available for subscribers to premium news services.
Advertisement

EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law

https://www.businesswire.com/news/home/20261012438298/en/EOLS-Investors-with-%24100000-in-Losses-Have-Opportunity-to-Join-Evolus-Inc.-Fraud-Investigation-with-SBS-Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Evolus, Inc. (NASDAQ: EOLS) following a warning letter from the FDA regarding the company's Instagram promotion of its wrinkle treatment, Jeuveau. The FDA cited Evolus for minimizing safety information and making misleading claims. Investors who suffered losses, particularly those with $100,000 or more, are encouraged to contact SBS to discuss their rights.

Trading Systems Reacting to (EOLS) Volatility

https://news.stocktradersdaily.com/news_release/21/Trading_Systems_Reacting_to_EOLS_Volatility_101126025201_1791744721.html
Stock Traders Daily's AI models have identified volatility in Evolus Inc. (NASDAQ: EOLS), generating three distinct trading strategies for different risk profiles. The analysis points to a positive near-term sentiment that may counter a mid-term weak bias within a broader long-term strength context, highlighting an exceptional risk-reward setup.

UTMD Trades at a Premium to the Industry: How to Play the Stock?

https://www.tradingview.com/news/zacks:5607f0b95094b:0-utmd-trades-at-a-premium-to-the-industry-how-to-play-the-stock/
Utah Medical Products, Inc. (UTMD) is currently trading at a premium valuation compared to its industry peers, which raises questions for investors despite its long-term potential. The company's recent acquisition, strong financial position, and consistent shareholder distributions are positive indicators, but it faces near-term challenges such as revenue decline and increased costs. Investors are advised to consider its strong fundamentals for long-term holding, but potentially await a better entry point due to its high valuation.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-evolus-inc---eols-302902096.html
Pomerantz LLP is investigating potential securities fraud claims against Evolus, Inc. (NASDAQ: EOLS) after a warning letter from the U.S. Food and Drug Administration (FDA) was disclosed on October 2, 2026. The FDA flagged an Instagram promotion for Evolus's wrinkle treatment Jeuveau as false or misleading, leading to a 7.15% drop in Evolus's stock price. Investors affected by the stock drop are encouraged to contact Pomerantz LLP for information regarding a potential class action lawsuit.

Evolus Instagram Reel Comparing Botox Rival Jeuveau to Beauty Products Drew an FDA Letter Over Downplayed Risks

https://www.medicaldaily.com/fda-evolus-jeuveau-instagram-ad-untitled-letter-risks-479611
The FDA issued an untitled letter to Evolus regarding an Instagram reel promoting its wrinkle injection, Jeuveau. The agency stated that the reel misbranded the drug by comparing it to everyday beauty products and downplaying its risks, particularly its boxed warning. The FDA is concerned that this marketing approach could lead consumers to misunderstand the serious nature of the prescription product and the potential dangers associated with its use.
Advertisement

FDA flags Evolus' Jeuveau Instagram reel for blurring the line between Rx injectable and beauty bag

https://www.mmm-online.com/news/fda-flags-evolus-jeuveau-instagram-reel-rx-injectable-beauty-bag/
The FDA has flagged an Instagram reel for Evolus' frown-line injectable, Jeuveau, accusing the company of misleading consumers. The regulator criticized the reel for overstating the drug's efficacy and speed, and for marketing a prescription neurotoxin as casually as a beauty product, thereby minimizing risks. This action is part of a sustained crackdown by the FDA on deceptive drug advertising.

Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug - Evolus (NASDAQ:EOLS)

https://www.benzinga.com/news/health-care/26/10/62143276/evolus-warned-over-misbranding-in-social-media-promo-for-frown-lines-drug
The U.S. FDA's Office of Prescription Drug Promotion issued a warning letter to Evolus Inc. regarding misleading Instagram promotions for its frown line treatment, Jeuveau. The agency found that the social media content exaggerated efficacy, downplayed safety risks, and improperly compared the prescription drug to cosmetic items. Evolus has been given 15 working days to respond with a plan to address the violative promotional materials.

FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action

https://finance.yahoo.com/healthcare/articles/fda-flags-evolus-jeuveau-instagram-174117439.html
The FDA has flagged an Instagram promotion for Evolus' (EOLS) wrinkle treatment, Jeuveau, as "false or misleading," causing the company's shares to fall. The agency objected to claims about "gone" frown lines, "complete results," and rapid action, stating that supporting studies primarily measured efficacy at Day 30, not Day 2. Evolus has been given 15 working days to respond and outline corrective actions for its promotional materials.

Evolus (EOLS) Shares Fall After FDA Warning on Jeuveau Instagram Post

https://www.gurufocus.com/news/9107730/evolus-eols-shares-fall-after-fda-warning-on-jeuveau-instagram-post
Evolus (EOLS) shares dropped after the FDA issued a warning regarding a misleading Instagram post for its product, Jeuveau, requiring a corrective action plan. The company's Price-to-Sales ratio is low compared to its historical median, reflecting market skepticism, and traditional P/E metrics are not applicable due to ongoing losses. While institutional gurus show some confidence, insiders have been net sellers, presenting a complex and speculative investment picture for Evolus.

Evolus Inc (0K16) Q3 2024 Earnings Report - Results, Call & Slides

https://www.tipranks.com/stocks/gb:0k16/earnings/q3-2024-report
Evolus Inc (0K16) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -$0.16 against a consensus of -$0.12, and actual revenue of $61.09M compared to an expected $63.17M, though revenue still grew 22.12% year-over-year. The earnings call took place on November 6, 2024, and the next earnings report is estimated for November 10, 2026.
Advertisement

Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes

https://finance.yahoo.com/healthcare/articles/evolus-launches-wings-evolus-charitable-123000070.html
Evolus, Inc. has launched "Wings by Evolus," a new charitable platform to mobilize its community of aesthetic practices, providers, and patients for important causes. The first initiative will support Look Good Feel Better® during Breast Cancer Awareness Month in October 2026, with Evolus donating $1 for every patient check-in at participating practices. This platform aims to leverage the collective strength of the Evolus community to create a positive impact, starting with an organization that helps cancer patients manage appearance-related treatment effects and restore confidence.

At participating practices, each patient check-in will send $1 to cancer support.

https://www.stocktitan.net/news/EOLS/evolus-launches-wings-by-evolus-a-new-charitable-platform-to-k175zs910to8.html
Evolus (EOLS) has launched "Wings by Evolus," a new charitable platform designed to unite aesthetic practices, providers, and patients to support various causes. The first initiative, in honor of Breast Cancer Awareness Month, will support Look Good Feel Better, a global cancer support program. Throughout October, Evolus will donate $1 to the Look Good Feel Better Foundation for every Evolus Rewards patient check-in at participating practices.

How (EOLS) Movements Inform Risk Allocation Models

https://news.stocktradersdaily.com/news_release/1/How_EOLS_Movements_Inform_Risk_Allocation_Models_100126082202_1790857322.html
The article discusses how Evolus Inc. (EOLS) stock movements inform risk allocation models, highlighting divergent sentiment across different time horizons, suggesting choppy conditions. It presents three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for various risk profiles, along with multi-timeframe signal analysis. The analysis indicates a significant 79.5:1 risk-reward short setup, targeting an 18.4% downside with minimal risk.

Evolus Inc (EOLS-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/EOLS/
This article provides stock information and recent news for Evolus Inc. (EOLS-Q), a medical aesthetics company specializing in injectable botulinum toxin products. It lists current stock data, financial figures, and a compilation of news articles from various sources covering analyst ratings, earnings calls, product distribution agreements, and safety studies related to Evolus.

Discover Evolus And Two Other Growth Companies With Strong Insider Backing

https://www.webull.com/news/15594791994131456
This article identifies three growth companies—Evolus (EOLS), Forbright (FRBT), and Ryan Specialty Holdings (RYAN)—with significant insider ownership that may signal confidence in their future success. Evolus, a performance beauty company, is forecasted for 69.8% annual earnings growth and recently raised its 2026 guidance. Forbright, a bank holding company, is expected to see 37.6% annual earnings growth and is trading at a discount to its estimated fair value. Ryan Specialty Holdings, an insurance service provider, projects 44.8% annual earnings growth, though its revenue growth is slower than the market average.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement